Διεθνής αναγνώριση για τον Αιτωλοακαρνάνα πνευμονολόγο Δημοσθένη Μπούρο

-Ήταν προσκεκλημένος και παρουσίασε στο ετήσιο συνέδριο της Ευρωπαϊκής πνευμονολογικής Εταιρίας που πραγματοποιήθηκε στο Μόναχο στις 5-10 Σεπτεμβρίου 2014, με συμμετοχή 23.000 επιστημόνων, την μελέτη: «Τα βλαστοκύτταρα στην πνευμονική ίνωση»

-Σε ειδική τελετή αναγορεύτηκε μεταξύ των ιδρυτικών μελών της ευρωπαϊκής πνευμονολογικής εταιρείας (FERS: FOUNDATIONMEMBERS)

   Ο Αιτωλοακαρνάνας καθηγητής πνευμονολογίας Δημοσθένης Μπούρος των πανεπιστήμιων Κρήτης, Θράκης, Αθήνας, ο οποίος κατάγεται από την Σταμνά Μεσολογγίου, ήταν προσκεκλημένος και παρουσίασε στο ετήσιο συνέδριο της Ευρωπαϊκής πνευμονολογικής Εταιρίας που πραγματοποιήθηκε στο Μόναχο στις 5-10 Σεπτεμβρίου 2014, με συμμετοχή 23.000 επιστημόνων, μεταξύ αυτών και πολλοί Έλληνες πνευμονολόγοι, την μελέτη: «Τα βλαστοκύτταρα στην πνευμονική ίνωση».

     Παράλληλα σε ειδική τελετή αναγορεύτηκε μεταξύ των ιδρυτικών μελών της ευρωπαϊκής πνευμονολογικής εταιρείας (FERS: FOUNDATIONMEMBERS).

     Έτσι η χώρα μας εκπροσωπείται στα ιδρυτικά μέλη που θα επιλέγουν στο μέλλον τα νέα μέλη......

Fellowship of ERS: Nomination Form

FOUNDATION FELLOWSHIP

Section A: Candidate details

Candidate’s full name DEMOSTHENES BOUROS

Candidate’s current post PROFESSOR OF PNEUMONOLOGY, MEDICAL SCHOOL DEMOCRITUS UNIVERSITY OF THRACE HEAD,DEPARTMENT OF PNEUMONOLOGY  UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS, GREECE

Candidate’s contact details Postal address: DEMOSTHENES BOUROS MD,PhD, FCCP PROFESSOR OF PNEUMONOLOGY DEPARTMENT OF PNEUMONOLOGY  UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS ALEXANDROUPOLIS 68100 TEL/FAX: +30-25510-75096, 76106 MOBILE: +30-6944757616 WWW.PNEUMONALEX.GR WWW.PNEUMON.ORG Email:bouros@med.duth.gr,debouros@gmail.com

Section B: ERS Membership and other international contributions

Membership number: 2226 Year of membership:1983 Assembly: CLINICAL

Previous ERS roles

Leadership: ·         European Respiratory Society ·         National Delegate, European Respiratory Society. ·         Member of the council, European Respiratory Society. ·         Member of the nomination committee, European Respiratory Society. ·         Member of the long-range planning committee of the European Respiratory Society. Auditor, European Respiratory Society (1983-) (1999-2003) (2002-2003) (1999-2001) (2004-2008) Assembly: 01.05 Diffuse parenchymal Lung Disease 01.01 Clinical problems 10.02 Tuberculosis Committees: ERS Long range planning committee Editorial Boards: Respiratory Topic Named lectures and prizes: Invited lectures to ERS Other:

Other national/international roles

National societies: ·         Hellenic Thoracic Society ·         Hellenic Scientific Society for Rare Diseases and Orphan Drugs ·         Hellenic Society for Pulmonary Hypertension ·           Other international societies: ·         American Thoracic Society ·         American College of Chest Physicians ·         International Society Mucosal Immunology ·         International Society of Translational Medicine  Guideline panels: 1.      Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier   JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence- based guidelines for diagnosis and management. Am J RespirCrit Care Med. 2011 Mar 15;183(6):788-824. 2.      Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias.An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J RespirCrit Care Med. 2013 Sep 15;188(6):733-48. 3.      . Johnson SR1, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, Reynaud-Gaubert M, Boehler A, Brauner M, Popper H, Bonetti F, Kingswood C; Review Panel of the ERS LAM Task Force. Collaborators (42). European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosisEurRespir J. 2010 Jan;35(1):14-26 4.      Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al. Collaborator.Optimal assessment and management of chronic obstructive pulmonary disease (COPD).The European Respiratory Society Task Force.EurRespir J. 1995 Aug;8(8):1398-420

Section C: Research contribution

Summary of research achievements: <500 o:p="" words.="">

·         In a series of studies in patients with parapneumonic pleural effusions we have shown that early intervention, with a standard protocol, intrapleural instillation of fibrinolytics through a small bore pleural catheter is safe and effective mode of treatment.

·         My team has shown for the first time that in patients with idiopathic pulmonary fibrosis (IPF) global (in the blood) and local (in the bronchoalveolar lavage) T-regulatory cell (Tregs) are reduced compared with those of healthy volunteers and patients without IPF. The suppressor potential of BAL and blood Tregs was compromised in patients with IPF and patients with connective tissue disease pulmonary fibrosis (CTD-PF), compared with healthy volunteers and patients without IPF.Similarly, the Treg-induced suppression of helper T-cell type 1 and 2cytokine secretion was impaired in the BAL of patients with IPF andpatients with CTD-PF. Moreover, the defective function of BAL Tregscorrelated highly with parameters of disease severity.

·         My main research interest is the investigation of the pathogenesis of interstitial lung diseases and especially IPF. To this end, my cooperative team has shown that

o   The down-regulation of let-7d microRNA  in IPF and the profibrotic effects of this down-regulation in vitro and in vivo suggest a key regulatory role in preventing lung fibrosis.

o   The frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with IPF may be related to tumorigenesis.

o   The increased expression of proapoptotic molecules in epithelial cells in IPF that may be involved in the inadequate and delayed reepithelialization, which in turn contributes to fibroblast proliferation.

o   The decreased apoptotic rate of alveolar macrophages of patients with IPF is not associated with decreased expression of apoptosis mediators involved in the external or internal apoptotic pathway.

o   H2O2 and 8-isoprostane are increased in the EBC . H2O2 may be correlated with the severity of the disease in IPF.

o   EGFR is upregulated in the hyperplastic alveolar epithelium in fibrotic forms of idiopathic interstitial pneumonias (IIPs) indicating a potential role during abnormal reepithelization.

o   The inhibitor of growth family member 4 (ING4) hasa potential role in lung fibrogenesis.

o   The Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis, while the caspase-3-mediated gelsolin fragmentation was shown to be an apoptotic effector mechanism in disease pathogenesis and a marker of lung injury.

o   In terms of clinical research, our team at Royal Brompton Hospital in UK, has published the biggest series examining the histopathologic pattern in systemic sclerosis and their correlation to outcome.

o   We have published the first clinical trial to investigate the safety of cell therapy with adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Our ongoing clinical trial extends our observations in patients with COPD and in patients with combined pulmonary fibrosis-emphysema. This area of investigation is hot in pulmonary medicine, since it has been recognized that pneumonology lags behind other specialties (like hematology and cardiology) in the investigation of the role of stem cell application in devastating lung diseases.

List of top 10 publications: all authors, title, journal, citation number with one to two sentences describing the important of the reference. h-index (Web of Science): 41 (Scopus), Citations>6.700 1.      Bouros, D., Wells, A.U. , Nicholson, A.G., Colby, T.V., Polychronopoulos, V., Pantelidis, P., Haslam, P.L., Vassilakis, D.A., Black, C.M., Du Bois, R.M.Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome  (Article). American Journal of Respiratory and Critical Care Medicine. Volume 165, Issue 12, 15 June 2002, Pages 1581-1586. The biggest series examining the histopathologic pattern in systemic sclerosis and their correlation to outcome. Citations 350. 2.      Bouros, D., Schiza, S., Patsourakis, G., Chalkiadakis, G., Panagou, P., Siafakas, N.M. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: A prospective, double-blind study (Article). American Journal of Respiratory and Critical Care Medicine. Volume 155, Issue 1, 1997, Pages 291-295.The first comparative randomized trial to show the usefulness of Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions.Citations 185 3.      Bouros, D., Schiza, S., Tzanakis, N., Chalkiadakis, G., Drositis, J., Siafakas, N. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema: A randomized, double-blind study  (Article). American Journal of Respiratory and Critical Care Medicine. Volume 159, Issue 1, 1999, Pages 37-42.                                                                                                                      This study shows that the effect of this fibrinolytics is not by the volume effect of the instilled fluid, as was questioned by then in the literature. Citations 152. 4.      Pandit, K.V., Corcoran, D., Yousef, H., Yarlagadda, M., Tzouvelekis, A., Gibson, K.F., Konishi, K., Yousem, S.A., Singh, M., Handley, D., Richards, T., Selman, M., Watkins, S.C.f, Pardo, A., Ben-Yehudah, A., Bouros, D., Eickelberg, O., Ray, P., Benos, P.V. , Kaminski, N. Inhibition and role of let-7d in idiopathic pulmonary fibrosis  (Article).American Journal of Respiratory and Critical Care Medicine. Volume 182, Issue 2, 15 July 2010, Pages 220-229.                                                                                     This multicenter study shows that the down-regulation of let-7d in IPF and the profibrotic effects of this down-regulation in vitro and in vivo suggest a key regulatory role in preventing lung fibrosis.Citations 110. 5.      Kotsianidis, I., Nakou, E., Bouchliou, I., Tzouvelekis, A., Spanoudakis, E., Steiropoulos, P., Sotiriou, I., Aidinis, V., Margaritis, D., Tsatalas, C., Bouros, D. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis  (Article). American Journal of Respiratory and Critical Care Medicine. Volume 179, Issue 12, 15 June 2009, Pages 1121-1130.                                                                                                                     This study provides the first evidence of global (in blood) and local (in bronchoalveolar lavage) T-regulatory cell impairment in IPF that strongly correlates with disease severity, suggesting a role for Tregs in the fibrotic process. Citations 55 6.      Bouros, D., Pare, P., Panagou, P., Tsintiris, K., Siafakas, N. The varied manifestation of pulmonary artery agenesis in adulthood (Article). Chest, Volume 108, Issue 3, 1995, Pages 670-676.                                                                                                                            This clinical paper describes in detail the many faces of pulmonary artery agenesis in adulthood. Citations 100. 7.      Plataki, M., Koutsopoulos, A.V., Darivianaki, K., Delides, G., Siafakas, N.M., Bouros, D. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis  (Article).  Chest. Volume 127, Issue 1, 2005, Pages 266-274. This research article shows the increased expression of proapoptotic molecules in epithelial cells in IPF that may be involved in the inadequate and delayed reepithelialization, which in turn contributes to fibroblast proliferation.Citations 95 8.      Psathakis, K., Mermigkis, D., Papatheodorou, G., Loukides, S., Panagou, P, Polychronopoulos, V., Siafakas ,  N.M., Bouros, D. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis  (Article). European Journal of Clinical Investigation. Volume 36, Issue 5, May 2006, Pages 362-367. The data suggest that H2O2 and 8-isoprostane are increased in the EBC of patients with IPF. H2O2 may be correlated with the severity of the disease in IPF.Citations 55 9.      Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med. 2014 Jan;2(1):17-9.Invited paper presenting breakthrough research in the area of idiopathic pulmonary fibrosis. 10.  Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, Kolios G, Bouros D.A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.J Transl Med. 2013 Jul 15;11:171.The first clinical trial to investigate the safetyof adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Section D: Candidates brief curriculum vitae

Full name and title: Professor and Head Date of birth:      1-9-1951                                 Gender: male Currentpost:   PROFESSOR OF PNEUMONOLOGY MEDICAL SCHOOL DEMOCRITUS UNIVERSITY OF THRACE HEAD,DEPARTMENT OF PNEUMONOLOGY  UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS ALEXANDROUPOLIS 68100 TEL/FAX: +30-25510-75096, 76106 MOBILE: +30-6944757616 WWW.PNEUMONALEX.GR WWW.PNEUMON.ORG Previous posts (with dates): ·         Director , 401 Army general Hospital, Athens, Greece, 1985-1986 and  1987-1990 ·         Assistant professor, Medical School, University of Crete Greece, and deputy director Dept.  of Pneumonology, University Hospital of Crete, 1990-1995 ·         Associate professorand deputy director, Medical School, University of Crete Greece, and deputy director Dept.  of Pneumonology, University Hospital of Crete, 1995-2002 ·         Chair, Dept. of Clinical Pharmacology, Medical School, University of Crete, Greece, 1992-2012 ·         Professor and Head, Dept. of Pneumonology, Medical School, Democritus University of Thrace and Head Dept.  of Pneumonology, University Hospital of Alexandroupolis, Greece 2002-2014. ·         Vice president, Research Institute of Diseases of the Chest, 2009-2013 ·         Member of the board, University Hospital of Alexandroupolis, Greece, 2009-2014 ·         Chair, Dept. of internal Medicine, University Hospital of Heraklion, Crete, Greece, 200-2002 ·         Chair, Dept. of internal Medicine, University Hospital of Alexandroupolis, Greece, 2006-2014 Initial university/medical school (with dates): Aristotle University of Thessaloniki, 1969-1975 Degrees awarded (with awarding body and dates): ·         MD, Aristotle University of Thessaloniki, Medical Diploma, 1969-1975 ·         PhD, National University of Athens, 1980-1984 ·         Visiting Assistant Professor, Medical School, Boston University, 1986-1987 ·         Research fellow, Medical School, Harvard University, 1987-1988 ·         Research associate, Imperial College, UK and Royal Brompton Hospital, London, UK, 1998-1999 Honours, prizes, distinctions: ·         ERS Visiting Professor, Medical University of Vienna, Austria 2000

Section E: Contributions to education and clinical practice

Education: ·         24 years as a teacher and mentor to graduate and undergraduate students of the Medical Schools of the University of Crete and at Democritus University of Thrace, Greece, teaching physiology and pathophysiology of the respiratory tract system, pulmonary medicine, clinical pharmacology and therapeutics. ·         Director and teacher of two postgraduate programs at Democritus University of Thrace entitled “Clinical Pharmacology and Therapeutics” and “Sleep Medicine”. ·         My department organizes, for many years now, yearly hands on teaching seminars in Medical Thoracoscopy under the guidance of the European Respiratory Society. ·         I have participated as a teacher in a number of ERS School seminars. Clinicalpractice: ·         Director for 20 years of Pulmonary Departments in Greece (Athens, Heraklion, Alexandroupolis). ·         Establishment and operation centers of excellence for Interstitial Lung Diseases Units at the University Hospitals of Heraklion and Alexandroupolis. ·         Establishment and operation of state of the art Interventional PulmonologyUnit in my Department. ·         My department is a referral center for Interstitial Lung Disease and a Centre of Excellence for Idiopathic Pulmonary Fibrosis and also offer advanced Interventional Pulmonology and Pleural Disease services, including Fiberoptic Bronchoscopy, therapeutic rigid Bronchoscopy and Medical Thoracoscopy.The sleep lab has 4 beds and contributing to patients’ evaluation and treatment. The oncology unit offers day care chemotherapy to lung cancer patients. ·         My department is the only University Clinic in the area of Eastern Macedonia and Thrace, is on duty on a daily basis, while patients from other parts of Greece and abroad are referred to our department. About 2.000 patients are referred and hospitalized in the department each year. The outpatients’ clinic examines more than 5.000 patients each year.